Filtered By:
Specialty: Cardiology
Condition: Diabetes Type 2

This page shows you your search results in order of relevance. This is page number 11.

Order by Relevance | Date

Total 574 results found since Jan 2013.

Harmony Outcomes: A randomized, double blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus —rationale, design, and baseline characteristics
Conclusions Harmony Outcomes will assess the CV safety of albiglutide in patients with T2DM and CV disease. Trials of other agents in the GLP-1 RA class have shown CV benefit for only some of these medications, possibly due to differences in trial design or instead due to differences in drug structure or metabolism. Harmony Outcomes will provide information critical to our understanding of this heterogenous class of glucose-lowering agents.
Source: American Heart Journal - June 13, 2018 Category: Cardiology Source Type: research

Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function: Data from the CANVAS Program.
Conclusions : The effect of canagliflozin on cardiovascular and renal outcomes was not modified by baseline level of kidney function in people with type 2 diabetes and a history or high risk of cardiovascular disease down to eGFR levels of 30 mL/min/1.73 m2 Reassessing current limitations on the use of canagliflozin in CKD may allow additional individuals to benefit from this therapy. Clinical Trial Registration : URL: https://clinicaltrials.gov. Unique identifiers: NCT01032629, NCT01989754. PMID: 29941478 [PubMed - as supplied by publisher]
Source: Circulation - June 25, 2018 Category: Cardiology Authors: Neuen BL, Ohkuma T, Neal B, Matthews DR, de Zeeuw D, Mahaffey KW, Fulcher G, Desai M, Li Q, Deng H, Rosenthal N, Jardine MJ, Bakris G, Perkovic V Tags: Circulation Source Type: research

Harmony Outcomes: A randomized, double blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus—rationale, design, and baseline characteristics
ConclusionsHarmony Outcomes will assess the CV safety of albiglutide in patients with T2DM and CV disease. Trials of other agents in the GLP-1 RA class have shown CV benefit for only some of these medications, possibly due to differences in trial design or instead due to differences in drug structure or metabolism. Harmony Outcomes will provide information critical to our understanding of this heterogenous class of glucose-lowering agents.
Source: American Heart Journal - July 5, 2018 Category: Cardiology Source Type: research

Harmony Outcomes: A randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus—Rationale, design, and baseline characteristics
ConclusionsHarmony Outcomes will assess the CV safety of albiglutide in patients with T2DM and CV disease. Trials of other agents in the glucagon-like peptide-1 receptor agonist class have shown CV benefit for only some of these medications, possibly due to differences in trial design or instead due to differences in drug structure or metabolism. Harmony Outcomes will provide information critical to our understanding of this heterogenous class of glucose-lowering agents.
Source: American Heart Journal - July 10, 2018 Category: Cardiology Source Type: research

Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease.
CONCLUSIONS: Liraglutide added to standard of care reduced the risk for major cardiovascular events and all-cause mortality in patients with type 2 diabetes mellitus and chronic kidney disease. These results appear to apply across the chronic kidney disease spectrum enrolled. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov/ . Unique identifier: NCT01179048. PMID: 30566006 [PubMed - in process]
Source: Circulation - December 18, 2018 Category: Cardiology Authors: Mann JFE, Fonseca V, Mosenzon O, Raz I, Goldman B, Idorn T, von Scholten BJ, Poulter NR Tags: Circulation Source Type: research

Nut Consumption in Relation to Cardiovascular Disease Incidence and Mortality among Patients with Diabetes Mellitus.
CONCLUSIONS: Higher consumption of nuts, especially tree nuts, is associated with lower CVD incidence and mortality among participants with diabetes. These data provide novel evidence that supports the recommendation of incorporating nuts into healthy dietary patterns for the prevention of CVD complications and premature deaths among individuals with diabetes. PMID: 30776978 [PubMed - as supplied by publisher]
Source: Circulation Research - February 19, 2019 Category: Cardiology Authors: Liu G, Guasch-Ferre M, Hu Y, Li Y, Hu FB, Rimm EB, Manson JE, Rexrode K, Sun Q Tags: Circ Res Source Type: research

Metformin Use and Clinical Outcomes among Patients with Diabetes with or without Heart Failure or Kidney Dysfunction: Observations from the SAVOR-TIMI 53 Trial.
CONCLUSIONS: In a cohort of 12,156 patients with T2DM and high CV risk, metformin use was associated with lower rates of all-cause mortality, including after adjustment for clinical variables and biomarkers, but not lower rates of the composite endpoint of CV death, MI, or ischemic stroke. This association was most apparent in patients without prior HF or moderate to severe CKD. CLINICAL TRIAL REGISTRATION: URL: https://clinicaltrials.gov Unique Identifier: NCT01107886. PMID: 31362530 [PubMed - as supplied by publisher]
Source: Circulation - July 30, 2019 Category: Cardiology Authors: Bergmark BA, Bhatt DL, McGuire DK, Cahn A, Mosenzon O, Steg PG, Im K, Kanevsky E, Gurmu Y, Raz I, Braunwald E, Scirica BM, SAVOR-TIMI 53 Steering Committee and Investigators Tags: Circulation Source Type: research

Prediction of individual life-years gained without cardiovascular events from lipid, blood pressure, glucose, and aspirin treatment based on data of more than 500  000 patients with Type 2 diabetes mellitus
ConclusionCardiovascular disease-free life expectancy and effects of lifelong prevention in terms of CVD-free life-years gained can be estimated for people with T2DM using readily available clinical characteristics. Predictions of individual-level treatment effects facilitate translation of trial results to individual patients.
Source: European Heart Journal - January 9, 2019 Category: Cardiology Source Type: research

Risk of Cardiovascular Outcomes in Type 2 Diabetes Patients Following Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-IRA Therapy.
Conclusions: Risk of residual confounding cannot be fully excluded. Individual therapeutic agents within each class may have different magnitudes of effect. In this large real-world cohort of diabetic patients already on GLP-1RA, addition of SGLT2i - compared to addition of sulfonylurea - conferred greater cardiovascular benefit. The magnitude of the cardiovascular risk reduction was comparable to the benefit seen in cardiovascular outcome trials of SGLT2i versus placebo where baseline GLP-1RA use was minimal. PMID: 33302723 [PubMed - as supplied by publisher]
Source: Circulation - December 11, 2020 Category: Cardiology Authors: Dave CV, Kim SC, Goldfine AB, Glynn RJ, Tong A, Patorno E Tags: Circulation Source Type: research

Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial
ConclusionRoutine ingestion by hypertensive patients of ≥1 prescribed BP-lowering medications at bedtime, as opposed to upon waking, results in improved ABP control (significantly enhanced decrease in asleep BP and increased sleep-time relative BP decline, i.e. BP dipping) and, most importantly, markedly diminished occurrence of major CVD events.Trial registrationClinicalTrials.gov, number NCT00741585. 
Source: European Heart Journal - October 22, 2019 Category: Cardiology Source Type: research

Cardiovascular efficacy and safety of dipeptidyl peptidase-4 inhibitors: A meta-analysis of cardiovascular outcome trials
CONCLUSION: DPP-4 inhibitors do not seem to confer any significant cardiovascular benefit for patients with T2DM, while they do not seem to be associated with a significant risk for any major cardiac arrhythmias, except for atrial flutter. Therefore, this drug class should not be the treatment of choice for patients with established cardiovascular disease or multiple risk factors, except for those cases when newer antidiabetics (glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors) are not tolerated, contraindicated or not affordable for the patient.PMID:34754403 | PMC:PMC8554356 | DOI:1...
Source: World Journal of Cardiology - November 10, 2021 Category: Cardiology Authors: Dimitrios Ioannis Patoulias Aristi Boulmpou Eleftherios Teperikidis Alexandra Katsimardou Fotios Siskos Michael Doumas Christodoulos E Papadopoulos Vassilios Vassilikos Source Type: research